About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 371 record(s)
Req # A-2021-000819
The Signal Assessment: Typical (conventional) antipsychotics and All-cause Mortality (2009).Organization: Health Canada
September 2022
Req # A-2021-000937
Information on a product presently considered for access by Health Canada's Special Access Program (SAP). All products containing PSMA-11. Both 68Ga-labelled and 18F-labelled. The following information from requests made for the period…Organization: Health Canada
September 2022
Req # A-2021-001240
According to the Health Canada Generic Submissions Under Review List, an Abbreviated New Drug Submission (ANDS) for degarelix acetate was submitted on or after October 1, 2018. Documents containing information regarding the mock-ups of every label…Organization: Health Canada
September 2022
Req # A-2021-001288
Disclosable Good Manufacturing Practices (GMP) inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the drug establishment licence GMP foreign evidence inspection of…Organization: Health Canada
September 2022
Req # A-2021-001768
The source data used in making policies related to mandatory vaccination against COVID-19 travel restrictions, namely in regard to the requirement for vaccination in order to travel within and out of Canada. All the data that the government relies…Organization: Health Canada
September 2022
Req # A-2021-001959
Respecting ATIA requests A-2021-000734, A-2021-001017, and A-2021-001140, please provide the following records: Health Product and Food Branch (HPFB) recommendations, and summary documents thereof, completed Extension Justification Form(s), records…Organization: Health Canada
September 2022
Req # A-2022-000243
Health Canada issued a public advisory (Identification #RA-64122) on April 28, 2022 advising that Apotex Inc. is recalling five lots of Apo-Acyclovir tablets, in 200 mg and 800 mg strengths, due to the presence of N-nitrosodimethylamine (NDMA) above…Organization: Health Canada
September 2022
Req # A-2022-000257
The number of rapid tests distributed to government employees by department for each month and for each product type since September 2020. The number of rapid tests distributed to the private sector by organization during the same timeframe.Organization: Health Canada
September 2022
Req # A-2022-000371
The Health Canada approval letter for Vertex Pharmaceutical's trial to be carried out in Canada: A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes (ClinicalTrials.gov Identifier: NCT04786262).Organization: Health Canada
September 2022
Req # A-2022-000391
Cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22 for the medicinal ingredient buprenorphine. Screening…Organization: Health Canada
September 2022